AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
The Readout Loud
Intro
This chapter explores key developments in the life sciences sector, including Genentech's closure of its cancer immunotherapy group and Pfizer's withdrawal of a sickle cell drug. It also discusses the upcoming approval of a schizophrenia treatment and includes insights on Johnson & Johnson's advancements in oncology.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode